Annual report pursuant to Section 13 and 15(d)

Oxford Finance Loan Agreement - Additional Information (Details)

v3.22.4
Oxford Finance Loan Agreement - Additional Information (Details)
12 Months Ended
Nov. 15, 2022
Jul. 03, 2022
Jul. 02, 2022
Dec. 23, 2020
USD ($)
$ / shares
shares
Feb. 12, 2020
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Debt Instrument [Line Items]                
Term loan           $ 40,000,000    
Warrants to purchase common stock | shares             211,709 211,709
Loan Agreement                
Debt Instrument [Line Items]                
Term loan, aggregate principal amount         $ 60,000,000.0      
Additional term loan advances, description         A $20.0 million term loan (first tranche) was funded on February 12, 2020, and another $20.0 million term loan (second tranche) was funded on December 23, 2020. As of December 31, 2022, the final $20.0 million tranche remained available under the Loan Agreement, at the sole discretion of the Lender      
Term loan, interest rate terms the floating annual rate for each term loan was amended to equal the greater of (i) 7.75% and (ii) the sum of (a) the 1-month CME Term SOFR reference rate, (b) 0.10%, and (c) 5.98%.       The term loan initially bore interest at an annual rate equal to the greater of (i) 7.75% and (ii) the sum of 5.98% and the greater of (A) one-month LIBOR or (B) 1.77%.      
Term loan, interest rate 7.75%       7.75%      
Term loan, effective interest rate 5.98%       5.98%      
Term loan, variable interest rate basis 1-month CME Term SOFR       one-month LIBOR      
Term loan, variable interest rate basis spread 0.10%       1.77%      
Term loan, maturity date         Feb. 01, 2025      
Extended interest only period upon consummation of merger and private placement   Mar. 01, 2024 Mar. 01, 2023          
Extended maturity date upon consummation of merger and private placement   Feb. 01, 2026 Feb. 01, 2025          
Extended interest only period upon achievement of certain milestones   Sep. 01, 2024            
Extended maturity upon consummation of merger and private placement   Aug. 01, 2026            
Term Loan, facilities fee         $ 300,000      
Term loan, final payment fee percentage         5.00%      
Warrant exercisable period from date of issuance           5 years    
Interest expense           $ 4,100,000 $ 3,900,000 $ 1,700,000
Loan Agreement | Advance Prepaid in First 12 Months                
Debt Instrument [Line Items]                
Term loan, prepayment fee, equal to percentage of the principal amount being prepaid         2.00%      
Loan Agreement | Advance Prepaid After 12 Months But Prior to 24 Months                
Debt Instrument [Line Items]                
Term loan, prepayment fee, equal to percentage of the principal amount being prepaid         1.00%      
Loan Agreement | Advance Prepaid After 24 Months But Prior to Maturity Date                
Debt Instrument [Line Items]                
Term loan, prepayment fee, equal to percentage of the principal amount being prepaid         0.50%      
Loan Agreement | First Loan Tranche                
Debt Instrument [Line Items]                
Term loan         $ 20,000,000.0      
Term Loan, facilities fee         $ 100,000      
Warrants to purchase common stock | shares         2,754      
Warrant exercise price of common stock per share | $ / shares         $ 72.60      
Fair value of warrants         $ 100,000      
Loan Agreement | First Loan Tranche | Expected volatility | Weighted Average                
Debt Instrument [Line Items]                
Fair value of weighted average volatility         75.43      
Loan Agreement | First Loan Tranche | Expected life (in years) | Weighted Average                
Debt Instrument [Line Items]                
Fair value of weighted expected term         5 years      
Loan Agreement | Second Loan Tranche                
Debt Instrument [Line Items]                
Term loan       $ 20,000,000.0        
Term Loan, facilities fee       $ 75,000        
Warrants to purchase common stock | shares       1,738        
Warrant exercise price of common stock per share | $ / shares       $ 115.00        
Fair value of warrants       $ 200,000        
Loan Agreement | Second Loan Tranche | Expected volatility | Weighted Average                
Debt Instrument [Line Items]                
Fair value of weighted average volatility       82.41        
Loan Agreement | Second Loan Tranche | Expected life (in years) | Weighted Average                
Debt Instrument [Line Items]                
Fair value of weighted expected term       5 years        
Loan Agreement | Final Loan Tranche                
Debt Instrument [Line Items]                
Each of available additional term loan advances           $ 20,000,000.0    
Loan Agreement | Third Loan Tranche                
Debt Instrument [Line Items]                
Term loan, facilities fee         $ 50,000